Why the study?
The authors aimed to study clinical data and outcomes of patients admitted with acute PE over a five-year period.
Does systemic thrombolysis improve outcomes or increase bleeding in patients with acute pulmonary embolism?
Does systemic thrombolysis improve outcomes or increase bleeding in patients with acute pulmonary embolism?
Non-guideline-directed use of systemic thrombolysis in acute pulmonary embolism is associated with a significantly increased risk of bleeding.
Answers are grounded in this paper and cite their sources.
Highlights the severe bleeding trade-off for off-guideline thrombolysis in acute pulmonary embolism.
Aim and Method We aimed to study the clinical data and outcome of patients admitted in our centre with acute pulmonary embolism (PE) over a five year period from May 2013 to April 2018. The main outcome data included were- in-hospital bleeding, in hospital RV function improvement, PAH improvement, duration of hospital stay, 30 and 90 day mortality. Results A total of 114 (69 m, 55 f) patients with the mean age of 55+/− 15 yrs were included. Patients who had involvement of central pulmonary trunk- called as “Central PE” group (n = 82) and others as “Peripheral PE” group (n = 32). There were more women in the peripheral PE group (53.1% vs 34.1%, p 0.05), while RBBB (22% vs 3.1%, p 0.02) and RV dysfunction (59.8% vs 25%, p 0.002) were noted more in the central PE group. Systemic thrombolysis was done in 53 patients (49 central, 4 peripheral), of which only 3 had hypotension and 28 patients were in the Intermediate-high risk group. The overall in-hospital, 30 day and 90 day mortality were 3.6, 13.2 and 22.8% respectively. Bleeding was significantly higher in thrombolysed group compared to the non- thrombolysed group (18.9% vs 0, p 0.0003). However, improvement in pulmonary hypertension was noted more in thrombolysis group compared to non-thrombolytic group. (49% vs 21.2%, p 0.01). Conclusion This retrospective data from a tertiary centre in South India showed that short and mid-term mortality of patients with PE still remains high. The high non-guideline use of thrombolysis has reflected in the increased bleeding noted in our study.
No takes yet. Share an insight, caveat, or question.
Showkathali et al. (2020) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: